NCT05140382 · OUTCOME
Maximum Observed Plasma (Peak) Drug Concentration (Cmax)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- Nanogram per milliliter (ng/mL)
- Interval / dispersion
- Geometric Coefficient of Variation
- Time frame
- Cycle 1 (Cycle length is 35 days), Day 1 of Weeks 1-3 and Cycle 2 (Cycle length is 21 Days), Day 1.
What was measured
The plasma PK of AZD4573 when administered in participants was assessed.
Analysis population: Pharmacokinetic (PK) set included all participants who received any amount of study intervention with at least 1 reportable concentration. Here, 'n" (number analyzed in each row) signifies the participants with available data that were analyzed for each timepoint of this outcome measure.
Groups in this outcome
Cohort 1 Non-NK PTCL
Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.
Cohort 2 NK PTCL
Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.
Cohort 3 cHL
Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.
| Group | Source count |
|---|---|
| Cohort 1 Non-NK PTCL | 31 |
| Cohort 2 NK PTCL | 2 |
| Cohort 3 cHL | 19 |
Reported measurements
Cycle 1 week 1 day 1
| Group | Source count |
|---|---|
| Cohort 1 Non-NK PTCL | 31 |
| Cohort 2 NK PTCL | 2 |
| Cohort 3 cHL | 19 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort 1 Non-NK PTCL | 159.9 | 53.2 | Not reported | Not reported | Not reported |
| Cohort 2 NK PTCL | NA | NA | Not reported | Not reported | Here, "NA" indicates that data could not be evaluated due to smaller number of participants. |
| Cohort 3 cHL | 201.8 | 82.1 | Not reported | Not reported | Not reported |
Cycle 1 week 2 day 1
| Group | Source count |
|---|---|
| Cohort 1 Non-NK PTCL | 25 |
| Cohort 2 NK PTCL | 1 |
| Cohort 3 cHL | 15 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort 1 Non-NK PTCL | 312.4 | 84.5 | Not reported | Not reported | Not reported |
| Cohort 2 NK PTCL | NA | NA | Not reported | Not reported | Here, "NA" indicates that data could not be evaluated due to smaller number of participants. |
| Cohort 3 cHL | 278.2 | 73.8 | Not reported | Not reported | Not reported |
Cycle 1 week 3 day 1
| Group | Source count |
|---|---|
| Cohort 1 Non-NK PTCL | 25 |
| Cohort 2 NK PTCL | 1 |
| Cohort 3 cHL | 16 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort 1 Non-NK PTCL | 265.5 | 54.1 | Not reported | Not reported | Not reported |
| Cohort 2 NK PTCL | NA | NA | Not reported | Not reported | Here, "NA" indicates that data could not be evaluated due to smaller number of participants. |
| Cohort 3 cHL | 376.3 | 89.9 | Not reported | Not reported | Not reported |
Cycle 2 day 1
| Group | Source count |
|---|---|
| Cohort 1 Non-NK PTCL | 16 |
| Cohort 2 NK PTCL | 0 |
| Cohort 3 cHL | 14 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort 1 Non-NK PTCL | 308.6 | 65.9 | Not reported | Not reported | Not reported |
| Cohort 3 cHL | 381.8 | 82.5 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 53.2
- value
- 159.9
- comment
- Here, "NA" indicates that data could not be evaluated due to smaller number of participants.
- group Id
- OG001
- spread
- NA
- value
- NA
- group Id
- OG002
- spread
- 82.1
- value
- 201.8
- denoms
- counts
- group Id
- OG000
- value
- 31
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 19
- units
- Participants
- title
- Cycle 1 week 1 day 1
- categories
- measurements
- group Id
- OG000
- spread
- 84.5
- value
- 312.4
- comment
- Here, "NA" indicates that data could not be evaluated due to smaller number of participants.
- group Id
- OG001
- spread
- NA
- value
- NA
- group Id
- OG002
- spread
- 73.8
- value
- 278.2
- denoms
- counts
- group Id
- OG000
- value
- 25
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 15
- units
- Participants
- title
- Cycle 1 week 2 day 1
- categories
- measurements
- group Id
- OG000
- spread
- 54.1
- value
- 265.5
- comment
- Here, "NA" indicates that data could not be evaluated due to smaller number of participants.
- group Id
- OG001
- spread
- NA
- value
- NA
- group Id
- OG002
- spread
- 89.9
- value
- 376.3
- denoms
- counts
- group Id
- OG000
- value
- 25
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 16
- units
- Participants
- title
- Cycle 1 week 3 day 1
- categories
- measurements
- group Id
- OG000
- spread
- 65.9
- value
- 308.6
- group Id
- OG002
- spread
- 82.5
- value
- 381.8
- denoms
- counts
- group Id
- OG000
- value
- 16
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 14
- units
- Participants
- title
- Cycle 2 day 1
- denoms
- counts
- group Id
- OG000
- value
- 31
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 19
- units
- Participants
- description
- The plasma PK of AZD4573 when administered in participants was assessed.
- dispersion Type
- Geometric Coefficient of Variation
- groups
- description
- Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.
- id
- OG000
- title
- Cohort 1 Non-NK PTCL
- description
- Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.
- id
- OG001
- title
- Cohort 2 NK PTCL
- description
- Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.
- id
- OG002
- title
- Cohort 3 cHL
- param Type
- GEOMETRIC_MEAN
- population Description
- Pharmacokinetic (PK) set included all participants who received any amount of study intervention with at least 1 reportable concentration. Here, 'n" (number analyzed in each row) signifies the participants with available data that were analyzed for each timepoint of this outcome measure.
- reporting Status
- POSTED
- time Frame
- Cycle 1 (Cycle length is 35 days), Day 1 of Weeks 1-3 and Cycle 2 (Cycle length is 21 Days), Day 1.
- title
- Maximum Observed Plasma (Peak) Drug Concentration (Cmax)
- type
- SECONDARY
- unit Of Measure
- Nanogram per milliliter (ng/mL)
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle